FR2182998A1 - - Google Patents

Info

Publication number
FR2182998A1
FR2182998A1 FR7314690A FR7314690A FR2182998A1 FR 2182998 A1 FR2182998 A1 FR 2182998A1 FR 7314690 A FR7314690 A FR 7314690A FR 7314690 A FR7314690 A FR 7314690A FR 2182998 A1 FR2182998 A1 FR 2182998A1
Authority
FR
France
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
FR7314690A
Other languages
French (fr)
Other versions
FR2182998B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merz and Co GmbH and Co KG
Original Assignee
Merz and Co GmbH and Co KG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE2219256A external-priority patent/DE2219256C3/de
Priority claimed from DE2318461A external-priority patent/DE2318461A1/de
Application filed by Merz and Co GmbH and Co KG filed Critical Merz and Co GmbH and Co KG
Publication of FR2182998A1 publication Critical patent/FR2182998A1/fr
Application granted granted Critical
Publication of FR2182998B1 publication Critical patent/FR2182998B1/fr
Expired legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/16Amides, e.g. hydroxamic acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
FR7314690A 1972-04-20 1973-04-20 Expired FR2182998B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE2219256A DE2219256C3 (de) 1972-04-20 1972-04-20 Oral und parenteral verabreichbares Arzneimittel zur Behandlung der Parkinson'sehen Krankheit
DE2318461A DE2318461A1 (de) 1973-04-12 1973-04-12 Verfahren zur herstellung von 1,3,5trisubstituierten adamanta-verbindungen

Publications (2)

Publication Number Publication Date
FR2182998A1 true FR2182998A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 1973-12-14
FR2182998B1 FR2182998B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 1976-12-31

Family

ID=25763107

Family Applications (1)

Application Number Title Priority Date Filing Date
FR7314690A Expired FR2182998B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 1972-04-20 1973-04-20

Country Status (8)

Country Link
US (1) US4122193A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
JP (1) JPS4918860A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CA (1) CA974518A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CH (1) CH603545A5 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
ES (1) ES413944A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
FR (1) FR2182998B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
GB (1) GB1393503A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
NL (1) NL7305644A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2445145A1 (fr) * 1978-12-27 1980-07-25 Merz & Co Compositions influencant le systeme nerveux central a base de 1,3-dimethyl-5-aminoadamantane et d'un compose de methylxanthine

Families Citing this family (90)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5334618A (en) * 1991-04-04 1994-08-02 The Children's Medical Center Corporation Method of preventing NMDA receptor-mediated neuronal damage
US5506231A (en) * 1989-03-31 1996-04-09 The Children's Medical Center Corporation Treatment of aids dementia, myelopathy and blindness
US5455279A (en) * 1991-04-19 1995-10-03 The Children's Medical Center Corporation Regimen method of mediating neuronal damage using nitroglycerine
WO1992017168A1 (en) * 1991-04-04 1992-10-15 The Children's Medical Center Corporation Method of preventing nmda receptor-mediated neuronal damage
US5614560A (en) * 1991-04-04 1997-03-25 Children's Medical Center Corporation Method of preventing NMDA receptor-mediated neuronal damage
DE4225730C2 (de) * 1992-08-04 2003-04-30 Merz Pharma Gmbh & Co Kgaa Verfahren zur Herstellung von festen Arzneiformkörpern mit protrahierter 2-Stufen-Freisetzung
US6057373A (en) * 1997-05-22 2000-05-02 Synchroneuron, Llc Methods of treating tardive dyskinesia and other movement disorders using NMDA receptor antagonists
US5866585A (en) * 1997-05-22 1999-02-02 Synchroneuron, Llc Methods of treating tardive dyskinesia using NMDA receptor antagonists
US5952389A (en) * 1998-01-13 1999-09-14 Synchroneuron Methods of treating tardive dyskinesia and other movement disorders
US6294583B1 (en) 1998-01-13 2001-09-25 Synchroneuron, Llc Methods of treating tardive dyskinesia and other movement disorders
US6444702B1 (en) 2000-02-22 2002-09-03 Neuromolecular, Inc. Aminoadamantane derivatives as therapeutic agents
WO2003015713A2 (en) * 2001-08-20 2003-02-27 Maiken Nedergaard Treatment of glial tumors with glutamate antagonists
EP1298581A1 (fr) * 2001-09-27 2003-04-02 C.S.E.M. Centre Suisse D'electronique Et De Microtechnique Sa Procédé et dispositif pour calculer les valeurs des neurones d'un réseau neuronal
KR100852834B1 (ko) 2002-10-24 2008-08-18 메르츠 파마 게엠베하 운트 코. 카가아 1-아미노시클로헥산 유도체 및 아세틸콜린에스테라제저해제를 포함하는 약학적 제품 및 이를 이용한 복합 치료
RU2246482C2 (ru) * 2002-12-25 2005-02-20 ООО "Циклан" Способ получения гидрохлорида 1-амино-3,5-диметиладамантана
UA80055C2 (en) * 2003-05-27 2007-08-10 Forest Laboratories Combination of nmda-receptor antagonist and selective inhibitor of serotonin reuptake for a depression and other pscihiatric disorders treatment
CN1240668C (zh) * 2003-09-10 2006-02-08 上海医药工业研究院 一种新的盐酸美金刚制备方法
CA2540921A1 (en) * 2003-10-22 2005-09-01 Merz Pharma Gmbh & Co. Kgaa The use of 1-aminocyclohexane derivatives to modify deposition of fibrillogenic ass peptides in amyloidopathies
AR046314A1 (es) 2003-11-05 2005-11-30 Merz Pharma Gmbh & Co Kgaa Composiciones que comprenden ciclohexilaminas y aminoadamantanos
WO2005069742A2 (en) * 2003-12-10 2005-08-04 Sun Pharmaceutical Industries Limited Crystal form ii of memantine hydrochloride
CA2551689A1 (en) * 2004-01-05 2005-07-28 Merz Pharma Gmbh & Co. Kgaa Memantine for the treatment of mild and mild-to-moderate alzheimer's disease
CN100363329C (zh) * 2004-01-09 2008-01-23 南京大学 合成美金刚胺盐酸盐的方法
US7456224B2 (en) * 2004-04-05 2008-11-25 Forest Laboratories Holdings, Ltd. Method for treating autism
EP1765287A2 (en) 2004-06-17 2007-03-28 Merz Pharma GmbH & Co. KGaA Immediate release formulations of memantine oral dosage forms
US20060002999A1 (en) 2004-06-17 2006-01-05 Forest Laboratories, Inc. Immediate release formulations of 1-aminocyclohexane compounds, memantine and neramexane
EP1781261A1 (en) * 2004-06-17 2007-05-09 Forest Laboratories, Inc. Modified release formulation of memantine
TW200616608A (en) * 2004-07-09 2006-06-01 Forest Laboratories Memantine as adjunctive treatment to atypical antipsychotics in schizophrenia patients
EP1799224A1 (en) * 2004-09-23 2007-06-27 Merz Pharma GmbH & Co.KGaA Memantine for the treatment of childhood behavioral disorders
US20060205822A1 (en) * 2004-12-22 2006-09-14 Forest Laboratories, Inc. 1-Aminocyclohexane derivatives for the treatment of multiple sclerosis, emotional lability and pseudobulbar affect
PT1836157E (pt) * 2005-01-11 2009-11-24 Teva Pharm Fine Chemicals Srl Polimorfos de cloridrato de memantina
ITMI20050833A1 (it) * 2005-05-10 2006-11-11 A M S A S P A Anonima Materie Sintetiche Affini Nuovo procedimento per la sintesi di aminoadamantani
EP1898890A1 (en) * 2005-06-16 2008-03-19 Forest Laboratories, Inc. Modified and immediate release memantine bead formulation
CA2659215C (en) 2005-07-27 2018-07-10 Dov Pharmaceutical, Inc. Novel 1-aryl-3-azabicyclo[3.1.0]hexanes: preparation and use to treat neuropsychiatric disorders
US20070099947A1 (en) * 2005-11-03 2007-05-03 Alkermes, Inc. Methods and compositions for the treatment of brain reward system disorders by combination therapy
ATE541827T1 (de) * 2006-02-21 2012-02-15 Hexal Ag Verfahren zur herstellung von adamantanaminen
MX2007014913A (es) * 2006-03-27 2008-10-24 Teva Pharma Proceso para perparar clorhidrato de memantina sustancialmente libre de impurezas.
PT2054416E (pt) 2006-08-04 2011-04-06 Merz Pharma Gmbh & Co Kgaa Pirazolopirimidinas substituídas, um processo para a sua preparação e a sua utilização como medicamento
EP1908748A1 (en) * 2006-10-05 2008-04-09 Krka Process for the preparation of memantine and its hydrochloric acid salt form
WO2008063847A2 (en) * 2006-11-03 2008-05-29 Forest Laboratories Holdings Limited Method for treating autism
MX2009006672A (es) 2006-12-19 2009-10-26 Univ Virginia Efectos combinados de topiramato y ondansetron sobre el consumo de alcohol.
CA2679263A1 (en) 2007-02-28 2008-09-04 Asahi Kasei Pharma Corporation Sulfonamide compound
US20090069374A1 (en) 2007-06-06 2009-03-12 Phil Skolnick Novel 1-Heteroaryl-3-Azabicyclo[3.1.0]Hexanes, Methods For Their Preparation And Their Use As Medicaments
US9133159B2 (en) 2007-06-06 2015-09-15 Neurovance, Inc. 1-heteroaryl-3-azabicyclo[3.1.0]hexanes, methods for their preparation and their use as medicaments
GB0713930D0 (en) 2007-07-18 2007-08-29 Generics Uk Ltd Novel assay methods
EP2090576A1 (en) 2008-02-01 2009-08-19 Merz Pharma GmbH & Co.KGaA 6-halo-pyrazolo[1,5-a]pyridines, a process for their preparation and their use as metabotropic glutamate receptor (mGluR) modulators
EP2085398A1 (en) 2008-02-01 2009-08-05 Merz Pharma GmbH & Co. KGaA Pyrazolopyrimidines, a process for their preparation and their use as medicine
WO2009151498A2 (en) * 2008-03-28 2009-12-17 Forest Laboratories Holdings Limited Memantine formulations
EP2288345B1 (en) 2008-04-18 2015-06-10 University College Dublin National University Of Ireland, Dublin Psycho-pharmaceuticals
EP2111858A1 (en) 2008-04-25 2009-10-28 EPFL Ecole Polytechnique Fédérale de Lausanne Novel treatment for alzheimer's disease
US20090275597A1 (en) * 2008-05-02 2009-11-05 Forest Laboratories Holdings Limited Methods of treating cns disorders
EP2138173A1 (en) 2008-06-26 2009-12-30 Merz Pharma GmbH & Co.KGaA Pharmaceutical compositions comprising aminoadamantane derivatives
JP5195256B2 (ja) * 2008-10-10 2013-05-08 東ソー株式会社 アミノアダマンタン誘導体の製造方法
HRP20090186A2 (hr) 2009-03-31 2010-10-31 Institut Ruđer Bošković Adamantanski bisureidni derivati, metoda priprave i primjena u detekciji aniona
WO2010112221A1 (en) 2009-04-03 2010-10-07 Synthon B.V. Pharmaceutical compositions comprising memantine
CN102070463A (zh) * 2009-06-11 2011-05-25 辽宁利锋科技开发有限公司 具有金刚烷结构药物美金刚胺及其衍生物和类似物抗肿瘤新适应症的应用
TW201116532A (en) 2009-08-05 2011-05-16 Merz Pharma Gmbh & Co Kgaa Metabotropic glutamate receptor modulators
US8741343B2 (en) 2009-12-02 2014-06-03 Adamas Pharmaceuticals, Inc. Method of administering amantadine prior to a sleep period
WO2011127235A1 (en) 2010-04-07 2011-10-13 Eisai Inc. Combination therapy for the treatment of dementia
AR083475A1 (es) 2010-10-18 2013-02-27 Merz Pharma Gmbh & Co Kgaa Moduladores de receptores de glutamato metabotropicos
CA2814905A1 (en) 2010-10-29 2012-05-03 Merz Pharma Gmbh & Co. Kgaa Indole derivatives and process for their preparation
NO3034079T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 2010-11-15 2018-06-09
WO2012085167A1 (en) 2010-12-22 2012-06-28 Merz Pharma Gmbh & Co. Kgaa Metabotropic glutamate receptor modulators
AR084516A1 (es) 2010-12-22 2013-05-22 Merz Pharma Gmbh & Co Kgaa Moduladores de receptores de glutamato metabotropicos
CN102241678B (zh) 2011-04-26 2014-10-29 辽宁利锋科技开发有限公司 含有脂环结构化合物的抗肿瘤作用与应用
WO2012152854A1 (en) 2011-05-12 2012-11-15 Merz Pharma Gmbh & Co. Kgaa Metabotropic glutamate receptor modulators
WO2012172093A1 (en) 2011-06-17 2012-12-20 Merz Pharma Gmbh & Co. Kgaa Dihydroindolizine derivate as metabotropic glutamate receptor modulators
US20140206740A1 (en) 2011-07-30 2014-07-24 Neurovance, Inc. Use Of (1R,5S)-(+)-(Napthalen-2-yl)-3-Azabicyclo[3.1.0]Hexane In The Treatment Of Conditions Affected By Monoamine Neurotransmitters
CN103288650B (zh) * 2012-02-28 2015-09-30 广州白云山制药股份有限公司广州白云山制药总厂 一种盐酸1-氨基-3,5-二甲基金刚烷的制备方法
EP2650284A1 (en) 2012-04-10 2013-10-16 Merz Pharma GmbH & Co. KGaA Heterocyclic derivatives as metabotropic glutamate receptor modulators
RU2488388C1 (ru) 2012-05-24 2013-07-27 Ооо "Валента Интеллект" Фармацевтическая композиция для профилактики и лечения психических, поведенческих, когнитивных расстройств
US10154971B2 (en) 2013-06-17 2018-12-18 Adamas Pharma, Llc Methods of administering amantadine
US9566264B2 (en) 2013-07-01 2017-02-14 Euthymics Bioscience, Inc. Combinations and methods
CN112409363B (zh) 2013-12-20 2023-11-14 艾吉因生物股份有限公司 用于治疗认知损害的苯并二氮杂䓬衍生物、组合物和方法
CA2938671A1 (en) 2014-02-04 2015-08-13 Forest Laboratories Holdings Limited Donepezil compositions and method of treating alzheimer's disease
MX384734B (es) 2015-06-19 2025-03-14 Agenebio Inc Derivados de benzodiazepina, composiciones y métodos para tratar deterioro cognitivo.
JP6354701B2 (ja) * 2015-08-19 2018-07-11 大日本印刷株式会社 高純度メマンチン塩酸塩の製造法
IL260290B2 (en) 2015-12-30 2023-11-01 Corium Inc Systems and methods for long-term percutaneous administration
US11541018B2 (en) 2016-06-23 2023-01-03 Corium, Llc Adhesive matrix with hydrophilic and hydrophobic domains and a therapeutic agent
AU2017302305A1 (en) 2016-07-27 2019-02-14 Corium, LLC. Transdermal delivery systems with pharmacokinetics bioequivalent to oral delivery
US9993466B2 (en) 2016-07-27 2018-06-12 Corium International, Inc. Donepezil transdermal delivery system
WO2018022818A1 (en) 2016-07-27 2018-02-01 Corium International, Inc. Memantine transdermal delivery systems
US11505555B2 (en) 2016-12-19 2022-11-22 Agenebio, Inc. Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
US20180170941A1 (en) 2016-12-19 2018-06-21 Agenebio, Inc. Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
US10369187B2 (en) 2017-02-09 2019-08-06 Vanderbilt University Peptide regulators of JNK family kinases
JP2019094304A (ja) * 2017-11-27 2019-06-20 学校法人順天堂 オートファジー誘導剤
US11173132B2 (en) 2017-12-20 2021-11-16 Corium, Inc. Transdermal adhesive composition comprising a volatile liquid therapeutic agent having low melting point
US11414425B2 (en) 2018-06-19 2022-08-16 Agenebio, Inc. Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
EP3721857A1 (en) * 2019-04-11 2020-10-14 Dentsply DeTrey GmbH Dental composition
WO2021232232A1 (zh) * 2020-05-19 2021-11-25 山东泓瑞医药科技股份公司 一种金刚烷胺的制备方法
IL319072A (en) 2022-08-19 2025-04-01 Agenebio Inc History of Benzazepine, Compositions and Methods for Treating Cognitive Impairment

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH76A (fr) * 1888-11-14 1889-01-09 Carnal Paul E Nouveau système de boîte de montre pouvant servir à volonté comme savonnette ou comme boîte à glace
US3391142A (en) * 1966-02-09 1968-07-02 Lilly Co Eli Adamantyl secondary amines

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR1545327A (fr) * 1966-11-25 1968-11-08 Boehringer Sohn Ingelheim Nouveau procédé de fabrication de 2-hydroxy-3-aryloxy-propylamines secondaires
US3450761A (en) * 1967-03-30 1969-06-17 Sun Oil Co 1-aminoethyldimethyladamantane
US3929888A (en) * 1968-08-27 1975-12-30 Lilly Industries Ltd 2-Phenyl-adamantanealkylamine compounds and their salts
US3789073A (en) * 1970-04-22 1974-01-29 Squibb & Sons Inc Adamantylalkylaminoalkyl benzamides

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH76A (fr) * 1888-11-14 1889-01-09 Carnal Paul E Nouveau système de boîte de montre pouvant servir à volonté comme savonnette ou comme boîte à glace
US3391142A (en) * 1966-02-09 1968-07-02 Lilly Co Eli Adamantyl secondary amines

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
(JOURNAL OF MEDICINAL CHEMISTRY 14, 1971 NO.6, PAGES 535-43. *
1972 33856F CITE: Z.CHEM.1971 11 10, 382) *
M7597(BSM) *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2445145A1 (fr) * 1978-12-27 1980-07-25 Merz & Co Compositions influencant le systeme nerveux central a base de 1,3-dimethyl-5-aminoadamantane et d'un compose de methylxanthine

Also Published As

Publication number Publication date
CA974518A (en) 1975-09-16
GB1393503A (en) 1975-05-07
JPS4918860A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 1974-02-19
US4122193A (en) 1978-10-24
NL7305644A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 1973-10-23
FR2182998B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 1976-12-31
CH603545A5 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 1978-08-31
ES413944A1 (es) 1976-06-01

Similar Documents

Publication Publication Date Title
FR2182998B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
FR2167634A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CS164949B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CS161981B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
JPS5319371B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
JPS5018927Y2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
JPS4968912A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CS166838B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CS162244B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
JPS4842067U (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
JPS5227911Y2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
JPS524683Y2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
JPS5323811Y2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
JPS5521253B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CS164466B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
JPS4889497A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CS164439B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CS163955B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
JPS4894275A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CS161552B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CS157798B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
JPS4951539U (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
FR2172030A2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
JPS4955482U (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
JPS4958142U (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)

Legal Events

Date Code Title Description
AR Application made for restoration
BR Restoration of rights